Considerations from venous stenosis to metabolic underpinnings in Idiopathic Intracranial Hypertension
Cephalalgia · 2023
DOI: 10.1177/03331024231184445 ↗Kurz gefasst
Leserbrief in der Zeitschrift Cephalalgia, 2023. Verfasst von Mark Thaller und 3 weiteren Autor:innen. Beteiligte Einrichtung: Translational Brain Science, Institute of Metabolism and Systems Research, University of Birmingham, UK. Hauptthemen laut MEDLINE: Pseudotumor Cerebri, Intracranial Hypertension, Vascular Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sir Jules Thorn Charitable Trust.
Abstract (Originalsprache)
We read with interest the article by Fargen et al (1) questioning whether idiopathic intracranial hypertension (IIH) is indeed idiopathic, and their proposal that venous sinus stenosis (VSS) is a central to the underlying pathophysiology of raised intracranial pressure (ICP). The majority of women diagnosed with IIH are people living with obesity. Population studies have observed the increased incidence and prevalence of IIH in those with an increased body mass index (BMI) (2,3), and have found an elevated BMI to be directly associated with greater risk of a diagnosis of IIH (2). Furthermore, a relationship between BMI and visual outcomes has been established where severe papilloedema was noted in IIH patients with BMI >40kg/m and with every 10kg/m increase in BMI observed the odds of severe visual loss was increased by 1.4 times (4). The literature evidences other potential pathophysiological drivers for IIH, omitted from Fargen et al.’s review (1). Primarily, systemic hormonal dysregulation has been noted in IIH with a distinct profile of androgen excess identified. Hyperandrogenism, in particular testosterone, has been shown to be elevated in women with IIH compared to age, sex, and BMI matched women with polycystic ovarian syndrome and also age, sex and BMI matched women living with obesity. Testosterone is known to be a driver of the Naþ/KþATPase pump in the choroid plexus which directly increases cerebrospinal fluid (CSF) production (5). Secondly, metabolic disturbances suggesting a global metabolic dysregulation have been found to be evident in the CSF, serum and urine of people with IIH using proton nuclear magnetic resonance spectroscopy, in comparison to an age, sex and BMI matched control group. The CSF:serum urea ratio was observed to be altered with urea being shown to be lower in the CSF of IIH participants compared to controls; this was in correlation with ICP and headache severity. The CSF:serum urea ratio was found to be greatest in the acute phase during high ICP potentially as a compensatory mechanism to drive fluid out of the CSF (6). Finally, it has been observed that IIH has unique disease features which are not explained by obesity alone. In big data studies, where obese controls have been comparators, people with IIH have been shown to have a doubled risk of cardiovascular disease (2) and insulin resistance (7). People with IIH have been demonstrated to have reduced birth rates, increased incidence of gestational diabetes and preeclampsia as compared to controls (8). Reduction of ICP is one of the therapeutic aims in IIH. This has been successfully achieved, as evidenced through randomised control trials (RCT), with the carbonic anhydrase inhibitor acetazolamide (9), bariatric surgery (10), and most recently reported the Glucagonlike peptide-1 (GLP-1) receptor agonist, Exenatide (11). While dural VSS (DVSS) (12), and indeed CSF shunting (13) have been shown to reduce ICP, none have been subject to the rigor of an RCT. Indeed, interventions to reduce the ICP alone have not been shown to alter the metabolic phenotype of truncal adiposity, insulin resistance, hyperleptinemia, fertility and pregnancy complications which typically remain if body weight is not lost. Consensus in IIH management has previously recommended interventional procedures are reserved for the specific indication of impending sight loss, where rapid resolution of raised ICP is required (14,15). Over the past two decades many authors, including Fargen et al. (1), have documented the presence of Cephalalgia 2023, Vol. 43(6) 1–3 ! International Headache Society 2023 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/03331024231184445 journals.sagepub.com/home/cep
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Translational Brain Science, Institute of Metabolism and Systems Research, University of Birmingham, UK.
- Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, UK.
- Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, UK.
- Institute of Metabolism and Systems Research, University of Birmingham, UK.
- Department of Neurosurgery, University Hospitals Birmingham NHS Foundation Trust, UK.
- Birmingham Neuro-Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, UK.
ORCID-Profile: Mark Thaller
Förderung
- Sir Jules Thorn Charitable Trust
Zitieren
APA
Thaller, M., Sinclair, A. J., Tsermoulas, G., & Mollan, S. P. (2023). Considerations from venous stenosis to metabolic underpinnings in Idiopathic Intracranial Hypertension. Cephalalgia. https://doi.org/10.1177/03331024231184445
Vancouver
Thaller M, Sinclair AJ, Tsermoulas G, Mollan SP. Considerations from venous stenosis to metabolic underpinnings in Idiopathic Intracranial Hypertension. Cephalalgia. 2023. doi:10.1177/03331024231184445
BibTeX
@article{Thaller2023,
author = {Thaller, Mark and Sinclair, Alexandra J and Tsermoulas, Georgios and Mollan, Susan P},
title = {Considerations from venous stenosis to metabolic underpinnings in Idiopathic Intracranial Hypertension},
journal = {Cephalalgia},
year = {2023},
doi = {10.1177/03331024231184445}
}
EUVIMED